Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice
- 1 September 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (9), 3195-3201
- https://doi.org/10.1128/aac.00153-08
Abstract
Intracellular concentrations of isoniazid and rifabutin resulting from administration of inhalable microparticles of these drugs to phorbol-differentiated THP-1 cells and the pharmacokinetics and biodistribution of these drugs upon inhalation of microparticles or intravenous administration of free drugs to mice were investigated. In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid (∼1.4 and 1.1 μg/10 6 cells) and rifabutin (∼2 μg/ml and ∼1.4 μg/10 6 cells) within 10 min. Microparticles maintained the intracellular concentration of isoniazid for 24 h and rifabutin for 96 h, whereas dissolved drugs did not. The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 μg of either drug, to parallel groups): isoniazid, serum half-life ( t 1/2 ) = 18.63 ± 5.89 h (3.91 ± 1.06 h), maximum concentration in serum ( C max ) = 2.37 ± 0.23 μg·ml −1 (3.24 ± 0.57 μg·ml −1 ), area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) = 55.34 ± 13.72 μg/ml −1 h −1 (16.64 ± 1.80 μg/ml −1 h −1 ), and clearance (CL) = 63.90 ± 13.32 ml·h −1 (4.43 ± 1.85 ml·h −1 ); rifabutin, t 1/2 = 119.49 ± 29.62 h (20.18 ± 4.02 h), C max = 1.59 ± 0.01 μg·ml −1 (3.47 ± 0.33 μg·ml −1 ), AUC 0-96 = 109.35 ± 14.78 μg/ml −1 h −1 (90.82 ± 7.46 μg/ml −1 h −1 ), and CL = 11.68 ± 7.00 ml·h −1 (1.03 ± 0.11 ml·h −1 ). Drug targeting to the lungs in general and alveolar macrophages in particular was observed. It was concluded that inhaled microparticles can reduce dose frequency and improve the pharmacologic index of the drug combination.This publication has 39 references indexed in Scilit:
- Long term efficacy of DOTS regimens for tuberculosis: systematic reviewBMJ, 2008
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- Enhancement of Apoptosis of THP-1 Cells Infected withMycobacterium tuberculosisby Inhalable Microparticles and Relevance to Bactericidal ActivityAntimicrobial Agents and Chemotherapy, 2007
- Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic PopulationsAntimicrobial Agents and Chemotherapy, 2007
- Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37RaJournal of Antimicrobial Chemotherapy, 2007
- Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette–GuérinMicrobes and Infection, 2006
- Clinical Pharmacokinetics of RifabutinClinical Pharmacokinetics, 1995
- RifabutinDrugs, 1994
- Clinical Pharmacokinetics of the Antituberculosis DrugsClinical Pharmacokinetics, 1984
- Clinical Pharmacokinetics of IsoniazidClinical Pharmacokinetics, 1979